Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic Purpura

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05585944

Enrollment

Registered

2022-10-19

Start date

2022-11-01

Completion date

2023-05-01

Last updated

2022-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune Thrombocytopenic Purpura

Brief summary

Immune thrombocytopenia is an acquired autoimmune disease, in which platelets are opsonized by auto-antibodies and destroyed by phagocytic cells .Genetic polymorphisms in the immune mediators have been suggested to play a pivotal role in the pathogenesis of many autoimmune disorders . Several genetic polymorphisms of the immune system genes have been described in ITP such as interleukins, tumor necrosis factors (TNF) alpha and beta, and interferon-gamma., These polymorphisms were found to be associated with an increased risk of ITP progression or exacerbation .CD40 is a co-stimulatory 4348 kDa glycoprotein molecule composed of 277 amino acid residues which belongs to the tumor necrosis family. It is encoded by a gene which is located at chromosome 20q11-13, expressed mainly on antigen presenting cells (APCs), some non-immune cells and tumors.Antinuclear antibodies (ANA) is a collective term for a large and heterogeneous group of circulating autoantibody. Reflecting their clinical importance, ANA are diagnostic, prognostic or classification criteria for many autoimmune diseases.

Interventions

DIAGNOSTIC_TESTGenotyping of rs1883832C/T related single-nucleotide polymorphism

Genotyping of rs1883832C/T related single-nucleotide polymorphism by real time pcr

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

1 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* sign an informed written consent from the patients or their parents * patient with newly diagnosed ITP * patient age \> 1 year and \< 65 years and both sexes are included.

Exclusion criteria

* Refusal to sign an informed written consent * patient with persistent ITP, patient with secondary immune thrombocytopenia * patient age \< 1 year or \> 65 years.

Design outcomes

Primary

Measure	Time frame	Description
rs1883832C/T related single-nucleotide polymorphism	6 months	effect of single-nucleotide polymorphism of CD40 gene (rs1883832 C/T) on the risk of immune thrombocytopenic purpura

Secondary

Measure	Time frame	Description
ANA	6 months	ANA in immune thrombocytopenic purpura

Countries

Egypt

Contacts

Primary Contactnagwa M Aboelmahasen, assisstant lecturer

nagwa.abdelaty@med.sohag.edu.eg01008831102

Backup ContactElham O Hamed, Professor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026